These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16614685)

  • 1. Macrolide-resistant Streptococcus pneumoniae: clinical implications for the empiric treatment of community-acquired respiratory tract infections.
    Brunton S; Iannini P
    MedGenMed; 2005 Dec; 7(4):63. PubMed ID: 16614685
    [No Abstract]   [Full Text] [Related]  

  • 2. Community-acquired upper respiratory tract infections and the role of third-generation oral cephalosporins.
    Hedrick JA
    Expert Rev Anti Infect Ther; 2010 Jan; 8(1):15-21. PubMed ID: 20014898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of antibiotic resistance in respiratory tract infections.
    Klugman KP
    Int J Antimicrob Agents; 2007 Feb; 29 Suppl 1():S6-10. PubMed ID: 17307654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel cost-effective approaches to the treatment of community-acquired infections.
    Schwarzmann SW
    Ann Pharmacother; 1998 Jan; 32(1):S27-30. PubMed ID: 9475837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hidden epidemic of macrolide-resistant pneumococci.
    Klugman KP; Lonks JR
    Emerg Infect Dis; 2005 Jun; 11(6):802-7. PubMed ID: 15963272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in vivo-in vitro paradox in pneumococcal respiratory tract infections.
    Bishai W
    J Antimicrob Chemother; 2002 Mar; 49(3):433-6. PubMed ID: 11864942
    [No Abstract]   [Full Text] [Related]  

  • 7. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
    Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
    J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic implications of macrolide resistance in pneumococcal community-acquired lower respiratory tract infections.
    Marrie TJ
    Int J Clin Pract; 2004 Aug; 58(8):769-76. PubMed ID: 15372850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program.
    Gordon KA; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2003 Aug; 46(4):285-9. PubMed ID: 12944021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [beta-lactam-antibiotics in the treatment of community-acquired respiratory tract infections with penicillin-resistant pneumococci].
    Brauers J; Ewig S; Kresken M
    Pneumologie; 2002 Oct; 56(10):605-9. PubMed ID: 12375222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary care challenges in the management of respiratory tract infections.
    JAAPA; 2006 Sep; Suppl():4-14; quiz 15-6. PubMed ID: 17001773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telithromycin (Ketek) for community-acquired respiratory tract infections.
    Wimett L; Laustsen G
    Nurse Pract; 2004 Sep; 29(9):56-60. PubMed ID: 15359148
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
    Hoban DJ; Zhanel GG
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical impact of macrolide resistance in pneumococcal respiratory infections.
    Garau J
    Int J Antimicrob Agents; 2001; 18 Suppl 1():S33-8. PubMed ID: 11574193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the relevance of antimicrobial resistance on the outcome of community-acquired pneumonia caused by Streptococcus pneumoniae? (should macrolide monotherapy be used for mild pneumonia?).
    Low DE
    Infect Dis Clin North Am; 2013 Mar; 27(1):87-97. PubMed ID: 23398867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Sentinel Project: an update on the prevalence of antimicrobial resistance in community-acquired respiratory Streptococcus pneumoniae and Haemophilus spp. in Italy.
    Marchese A; Ardito F; Fadda G; Fontana R; Lo Cascio G; Nicoletti G; Speciale AM; Schito GC
    Int J Antimicrob Agents; 2005 Jul; 26(1):8-12. PubMed ID: 15967638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes?
    Rothermel CD
    Clin Infect Dis; 2004 May; 38 Suppl 4():S346-9. PubMed ID: 15127368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of Macrolide-Induced Inhibition of Pneumolysin Release Involves Impairment of Autolysin Release in Macrolide-Resistant Streptococcus pneumoniae.
    Domon H; Maekawa T; Yonezawa D; Nagai K; Oda M; Yanagihara K; Terao Y
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30181369
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.